OKYO Pharma Limited Appointment of Chief Scientific Officer (7202T)
March 29 2021 - 1:00AM
UK Regulatory
TIDMOKYO
RNS Number : 7202T
OKYO Pharma Limited
29 March 2021
OKYO Pharma Limited
("OKYO" or the "Company")
OKYO announces appointment of Dr Rajkumar Patil as Chief
Scientific Officer
London, 29 March 2021 -OKYO (LSE: OKYO; OTCQB: EMMLF), the life
sciences and biotechnology company focused on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and ocular pain, announces that it has appointed Dr
Rajkumar Patil as Chief Scientific Officer.
Dr Patil brings 30 years of ophthalmic and pharmaceutical
R&D experience. Dr Patil worked with Ora Inc, as Vice President
of Research & Development, where he was responsible for driving
all anterior and posterior segment research of Ora's R&D
Institute. During 2013-2018, he worked at iVeena Delivery Systems
as Vice President of Advanced Ocular Delivery Systems. His term at
iVeena included a two-year sabbatical in Singapore, where he served
as an Associate Professor of Ophthalmology at DUKE/NUS Medical
School and Principal Investigator at Singapore Eye Research
Institute.
Further, Dr Patil has also held several leadership roles at
Alcon/Novartis Institute of Biomedical Research from 2004-2013,
including Associate Director of Research and Head of Molecular
Pharmacology glaucoma and retina research. Before joining Alcon, Dr
Patil served as an Associate Professor of Ophthalmology, Cell
Biology & Genetics at University of Nebraska Medical Centre in
Omaha and as an Assistant Professor of Ophthalmology, Molecular
Biology & Pharmacology at Washington University in St.
Louis.
Dr Patil received his PhD in Biochemistry from National Chemical
Laboratory/University of Pune, India and completed his postdoctoral
training in Biochemistry and Molecular Biology at the University of
Michigan, Ann Arbor, MI. He is the recipient of the Olga Keith
Wiess Special Scholar Award from the Research to Prevent Blindness
Foundation and NIH Director's New Innovator Award. Dr Patil has
authored over 50 peer-reviewed research articles and serves as
reviewer and editorial board member for numerous journals.
Dr Patil stated: "I am thrilled to join the OKYO team at this
exciting point in the growth of the company. Lack of adequate
treatments for dry eye and ocular allergy highly motivates me to
find better and safer therapies for these disorders. I am
specifically excited to lead the translational work supporting a
novel approach to develop Chemerin receptor GPCR agonist (OK-101)
that targets the inflammatory and analgesic pathways to treat dry
eye syndrome, uveitis and allergic conjunctivitis".
"We are very excited to have Dr Patil appointed as Chief
Scientific Officer at a very important time at OKYO," said Gary S
Jacob, CEO of OKYO. "Dr Patil has enormous experience in the
clinical development of ophthalmic drugs, and he will be
spearheading the development of our lead drug candidate, OK-101 to
treat dry eye disease, a major unmet medical need in the ophthalmic
space."
About OKYO
OKYO Pharma Limited (LSE: OKYO) is a life sciences and
biotechnology company admitted to listing on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the Main Market for listed securities of the London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and ocular pain.
Enquiries:
OKYO Pharma Limited Gary S Jacob, PhD +44 (0)20 7495 2379
Optiva Securities Limited Robert Emmet +44 (0)20 3981 4173
For further information, please visit the Company's website at
www.okyopharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUPWWUPGGPR
(END) Dow Jones Newswires
March 29, 2021 02:00 ET (06:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024